Collegium Pharmaceutical issues 2026 financial guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Collegium Provides 2026 Financial Guidance and Business Update
January 8, 2026 8:00 AM ESTProduct Revenues, Net Expected in the Range of $805 Million to $825 Million
Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million
Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million
STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update.
2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum for continued success,... More
